DelveInsight’s, “Brain Metastasis from Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from the Breast Cancer pipeline landscape. It covers the Brain Metastasis from Breast Cancer pipeline drug profiles, including Brain Metastasis from Breast Cancer clinical trials and nonclinical stage products. It also covers the Brain Metastasis from Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Brain Metastasis from Breast Cancer Pipeline treatment landscape of the report, click here @ Brain Metastasis from Breast Cancer Pipeline Outlook

 

Brain Metastasis from Breast Cancer Overview

Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.

 

Key Takeaways from the Brain Metastasis from Breast Cancer Pipeline Report

• DelveInsight’s Brain Metastasis from Breast Cancer Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Metastasis from Breast Cancer.
• The leading Brain Metastasis from Breast Cancer Companies include Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium Inc, Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others
• Promising Brain Metastasis from Breast Cancer Pipeline Therapies include Efaproxiral, NKTR-102, Eribulin, Ixabepilone, capecitabine, lapatinib, trastuzumab, and others
• Angiochem Inc. initiated a randomized, open-label, multi-center Phase III study to estimate if the drug ANG1005can prove to be effective in the long-term survival when compared to a physician’s best choice control in HER-2 negative breastcancer patients with newly diagnosed Leptomeningeal disease and treated with brain metastasis in the past. The study willcomprise of 150 participants and is estimated to get completed by Mach 2024.
• The Brain Metastasis from Breast Cancer companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastasis from Breast Cancer R&D. The Brain Metastasis from Breast Cancer therapies under development are focused on novel approaches to treat/improve Brain Metastasis from Breast Cancer.

 

For further information, refer to the detailed Brain Metastasis from Breast Cancer Unmet Needs, Brain Metastasis from Breast Cancer Market Drivers, and Brain Metastasis from Breast Cancer Market Barriers, click here for Brain Metastasis from Breast Cancer Ongoing Clinical Trial Analysis

 

Brain Metastasis from Breast Cancer Emerging Drugs Profile

 

• ANG1005: Angiochem

ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breast cancer.

 

• Pembrolizumab: Merck Sharp & Dohme

Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD⁠-⁠1 receptor, blocking both immune-suppressing ligands, PD‑L1 and PD‑L2, from interacting with PD⁠-⁠1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast Cancer Patients.

 

Request a sample and discover the recent advances in Brain Metastasis from Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Brain Metastasis from Breast Cancer Treatment Landscape

 

Brain Metastasis from Breast Cancer Pipeline Therapeutics Assessment

There are approx. 10+ Brain Metastasis from Breast Cancer companies which are developing the Brain Metastasis from Breast Cancer therapies. The Brain Metastasis from Breast Cancer companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Angiochem.

 

Dive deep into rich insights for drugs for Brain Metastasis from Breast Cancer Pipeline, click here @ Brain Metastasis from Breast Cancer Unmet Needs and Analyst Views

 

Scope of the Brain Metastasis from Breast Cancer Pipeline Report

• Coverage- Global
• Brain Metastasis from Breast Cancer Companies- Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium Inc, Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others
• Brain Metastasis from Breast Cancer Pipeline Therapies- Efaproxiral, NKTR-102, Eribulin, Ixabepilone, capecitabine, lapatinib, trastuzumab, and others.
• Brain Metastasis from Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Brain Metastasis from Breast Cancer Mergers and acquisitions, Brain Metastasis from Breast Cancer Licensing Activities @ Brain Metastasis from Breast Cancer Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Brain Metastasis from Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. ANG1005: Angiochem
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Pembrolizumab: Merck Sharp & Dohme
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Brain Metastasis from Breast Cancer Key Companies
17. Brain Metastasis from Breast Cancer Key Products
18. Brain Metastasis from Breast Cancer- Unmet Needs
19. Brain Metastasis from Breast Cancer- Market Drivers and Barriers
20. Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion
21. Brain Metastasis from Breast Cancer Analyst Views
22. Brain Metastasis from Breast Cancer Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services